Transfer of DCs from VAG539-tolerized mice inhibits allograft rejection. (A) CD90− antigen-presenting cells (VAG-APCs) or CD4+ T cells (VAG-CD4+) were purified from spleens of VAG539-treated graft-accepting mice, and CD90− antigen-presenting cells (saline APCs) were purified from spleens of saline-injected graft-rejecting mice 60 days after transplantation. Cells were injected (intravenously, 5 × 106 APCs or 3 × 106 T cells) into naive mice 1 day prior to islet transplantation. (B) CD11+ (VAG-DCs) or CD19+ (VAG-CD19) cells were purified from spleens of VAG539-treated graft-accepting mice 60 days after transplantation. As control, CD11c+ DCs were purified from spleens of saline-injected graft-rejecting mice 60 days after transplantation (saline-DCs) or of naive BALB/c mice (naive-DCs). Purified CD11c+ DCs (3 × 105) or CD19+ B cells (5 × 106) were injected intravenously 1 day before islet transplantation (2-tailed t test: **P < .01; *P < .05).
